309 related articles for article (PubMed ID: 20139095)
1. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C; Steward KK; Timmerman JM; Morrison SL
Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.
Trinh KR; Vasuthasawat A; Steward KK; Yamada RE; Timmerman JM; Morrison SL
J Immunother; 2013 Jun; 36(5):305-18. PubMed ID: 23719241
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
4. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
Blood; 2009 Oct; 114(18):3864-71. PubMed ID: 19710501
[TBL] [Abstract][Full Text] [Related]
5. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
[TBL] [Abstract][Full Text] [Related]
6. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.
Huang TH; Chintalacharuvu KR; Morrison SL
J Immunol; 2007 Nov; 179(10):6881-8. PubMed ID: 17982079
[TBL] [Abstract][Full Text] [Related]
7. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
8. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.
Li B; Zhao L; Guo H; Wang C; Zhang X; Wu L; Chen L; Tong Q; Qian W; Wang H; Guo Y
Blood; 2009 Dec; 114(24):5007-15. PubMed ID: 19828699
[TBL] [Abstract][Full Text] [Related]
11. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
12. Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.
Liao J; Luan Y; Ren Z; Liu X; Xue D; Xu H; Sun Z; Yang K; Peng H; Fu YX
Cancer Immunol Res; 2017 Jul; 5(7):560-570. PubMed ID: 28533311
[TBL] [Abstract][Full Text] [Related]
13. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
Vega GG; Franco-Cea LA; Huerta-Yepez S; Mayani H; Morrison SL; Bonavida B; Vega MI
Int J Oncol; 2015 Nov; 47(5):1735-48. PubMed ID: 26398317
[TBL] [Abstract][Full Text] [Related]
14. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
15. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies
Qin H; Wei G; Sakamaki I; Dong Z; Cheng WA; Smith DL; Wen F; Sun H; Kim K; Cha S; Bover L; Neelapu SS; Kwak LW
Clin Cancer Res; 2018 Mar; 24(5):1114-1123. PubMed ID: 29180606
[No Abstract] [Full Text] [Related]
16. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
17. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
18. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
[TBL] [Abstract][Full Text] [Related]
19. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
20. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Gopal AK; Press OW; Wilbur SM; Maloney DG; Pagel JM
Blood; 2008 Aug; 112(3):830-5. PubMed ID: 18502830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
